New generation vaccines /

New generation vaccines /

Saved in:
Bibliographic Details
Edition:3rd ed, rev. and expanded.
Imprint:New York : Marcel Dekker, 2004.
Description:xiii, 1117 p. : ill. ; 29 cm.
Language:English
Subject:
Vaccines.
Vaccines.
Format: Print Book
URL for this record:http://pi.lib.uchicago.edu/1001/cat/bib/5127906
Hidden Bibliographic Details
Other authors / contributors:Levine, Myron M. (Myron Max), 1944-
ISBN:0824740718 : No price
Notes:Includes bibliographical references and index.

MARC

LEADER 00000cam a2200000 a 4500
001 5127906
003 ICU
005 20050510170100.0
008 031208s2004 nyua b 001 0 eng
020 |a 0824740718 :  |c No price 
040 |a StDuBDS  |c StDuBDS  |d Uk  |d CStRLIN  |d CtY-M  |d OrLoB-B  |d UtOrBLW 
050 4 |a QR189  |b .N489 2004 
082 0 4 |a 615.372  |2 21 
245 0 0 |a New generation vaccines /  |c edited by Myron M. Levine ... [et al.]. 
250 |a 3rd ed, rev. and expanded. 
260 |a New York :  |b Marcel Dekker,  |c 2004. 
300 |a xiii, 1117 p. :  |b ill. ;  |c 29 cm. 
336 |a text  |b txt  |2 rdacontent  |0 http://id.loc.gov/vocabulary/contentTypes/txt 
337 |a unmediated  |b n  |2 rdamedia  |0 http://id.loc.gov/vocabulary/mediaTypes/n 
338 |a volume  |b nc  |2 rdacarrier  |0 http://id.loc.gov/vocabulary/carriers/nc 
504 |a Includes bibliographical references and index. 
505 0 0 |t Foreword /  |r Gustav J. V. Nossal --  |g 1.  |t Vaccines and Vaccination in Historical Perspective /  |r Myron M. Levine and Rosanna Lagos --  |g 2.  |t An Overview of Biotechnology in Vaccine Development /  |r James B. Kaper and Rino Rappuoli --  |g 3.  |t Initial Clinical Evaluation of New Vaccine Candidates: Investigators' Perspective of Phase I and II Clinical Trials of Safety, Immunogenicity, and Preliminary Efficacy /  |r Carol O. Tacket, Karen L. Kotloff and Margaret B. Rennels --  |g 4.  |t Long-Term Evaluation of Vaccine Protection: Methodological Issues for Phase III and IV Studies /  |r John D. Clemens, Abdollah Naficy, Malla R. Rao and Hye-won Koo --  |g 5.  |t Ethical Considerations in the Conduct of Vaccine Trials in Developing Countries /  |r Charles Weijer and Claudio F. Lanata --  |g 6.  |t Vaccine Economics: From Candidates to Commercialized Products in the Developing World /  |r Amie Batson, Piers Whitehead and Sarah Glass --  |g 7.  |t Development and Supply of Vaccines: An Industry Perspective /  |r Michel Greco --  |g 8.  |t Reaching Every Child - Achieving Equity in Global Immunization /  |r R. Bruce Aylward, M. Birmingham, J. Lloyd and B. Melgaard --  |g 9.  |t A Paradigm for International Cooperation: The Global Alliance for Vaccines and Immunization (GAVI) and the Vaccine Fund /  |r Lisa Jacobs, Jacques-Francois Martin and Tore Godal --  |g 10.  |t Economic Analyses of Vaccines and Vaccination Programs /  |r Benjamin Schwartz and Ismael Ortega-Sanchez --  |g 11.  |t The Role of the Food and Drug Administration in Vaccine Testing and Licensure /  |r Norman Baylor, Lydia A. Falk and Karen Midthun --  |g 12.  |t Developing Safe Vaccines /  |r Leslie K. Ball, Robert Ball and Bruce G. Gellin --  |g 13.  |t Polio Eradication: Capturing the Full Potential of a Vaccine /  |r R. Bruce Aylward, Rudolph Tangermann, Roland Sutter and Stephen L. Cochi --  |g 14.  |t Recent Advances in Immunology that Impact Vaccine Development /  |r Marcelo B. Sztein --  |g 15.  |t High-Throughout Informatics and In Vitro Assays for T-Cell Epitope Determination: Application to the Design of Epitope-Driven Vaccines /  |r Anne S. DeGroot, Hakima Sbai, William Martin, John Sidney, Alessandro Sette and Jay A. Berzofsky --  |g 16.  |t The Challenge of Inducing Protection in Very Young Infants /  |r Claire-Anne Siegrist --  |g 17.  |t Vaccination and Autoimmunity /  |r Paul-Henri Lambert and Michel Goldman --  |g 18.  |t Adjuvants for the Future /  |r Richard T. Kenney and Robert Edelman --  |g 19.  |t MF59 Adjuvant Emulsion /  |r Audino Podda and Giuseppe Del Giudice --  |g 20.  |t Immune-Enhancing Sequences (CpG Motifs), Cytokines, and Other Immunomodulatory Moieties /  |r Sanjay Gurunathan, Dennis M. Klinman and Robert A. Seder --  |g 21.  |t Use of Genetically Detoxified Mutants of Cholera and Escherichia coli Heat-Labile Enterotoxins as Mucosal Adjuvants /  |r Gordon Dougan and Gill Douce --  |g 22.  |t Recent Developments in Vaccine Delivery Systems /  |r Derek T. O'Hagan --  |g 23.  |t Proteosome Technology for Vaccines and Adjuvants /  |r George H. Lowell, David Burt, Greg White and Louis Fries --  |g 24.  |t Viruslike Particle (VLP) Vaccines /  |r Margaret E. Conner and Mary K. Estes --  |g 25.  |t Immunostimulating Reconstituted Influenza Virosomes /  |r Reinhard Glueck --  |g 26.  |t Plants as a Production and Delivery Vehicle for Orally Delivered Subunit Vaccines /  |r Tsafrir S. Mor, Hugh S. Mason, Dwayne D. Kirk, Charles J. Arntzen and Guy A. Cardineau --  |g 27.  |t Vaccinia Virus and Other Poxviruses as Live Vectors /  |r Bernard Moss --  |g 28.  |t Live Adenovirus Recombinants as Vaccine Vectors /  |r L. Jean Patterson, Bo Peng, Xinli Nan and Marjorie Robert-Guroff --  |g 29.  |t RNA Virus Replicon Vaccines /  |r Nancy L. Davis and Robert E. Johnston --  |g 30.  |t Attenuated Salmonella and Shigella as Live Vectors Carrying Either Prokaryotic or Eukaryotic Expression Systems /  |r James E. Galen, Marcela F. Pasetti, Marcelo B. Sztein, Eileen M. Barry and Myron M. Levine --  |g 31.  |t DNA Vaccines /  |r Indresh K. Srivastava, Margaret A. Liu and Jeffrey B. Ulmer --  |g 32.  |t DNA-Modified Virus Ankara and Other Heterologous Prime-Boost Immunization Strategies for Effector T Cell Induction /  |r Adrian V. S. Hill, Joerg Schneider and Andrew J. McMichael --  |g 33.  |t Mucosal Immunization and Needle-Free Injection Devices /  |r Myron M. Levine and James D. Campbell --  |g 34.  |t Transcutaneous Immunization /  |r Gregory M. Glenn and Richard T. Kenney --  |g 35.  |t Combination Vaccines for Routine Infant Immunization /  |r Margaret B. Rennels, Rosanna M. Lagos and Kathryn M. Edwards --  |g 36.  |t Meningococcal Conjugate and Protein-Based Vaccines /  |r Rino Rappuoli, Andrew J. Pollard and E. Richard Moxon --  |g 37.  |t The Postlicensure Impact of Haemophilus influenzae Type b and Serogroup C Neisseria meningitides Conjugate Vaccines /  |r Jay Wenger, Helen Campbell, Elizabeth Miller and David Salisbury --  |g 38.  |t Pneumococcal Protein-Polysaccharide Conjugate Vaccines /  |r Orin S. Levine, David L. Klein and Jay C. Butler --  |g 39.  |t Pneumococcal Common Proteins and Other Vaccine Strategies /  |r David E. Briles, James C. Paton and Susan K. Hollingshead --  |g 40.  |t Polysaccharide-Based Conjugate Vaccines for Enteric Bacterial Infections: Typhoid Fever, Nontyphoidal Salmonellosis, Shigellosis, Cholera, and Escherichia coli 0157 /  |r Shousun C. Szu, John B. Robbins, Rachel Schneerson, Vince Pozsgay and Chiayung Chu --  |g 41.  |t Attenuated Strains of Salmonella enterica serovar Typhi as Live Oral Vaccines Against Typhoid Fever /  |r Myron M. Levine, James Galen, Carol O. Tacket, Eileen M. Barry, Marcela F. Pasetti and Marcelo B. Sztein --  |g 42.  |t Vaccines Against Lyme Disease /  |r Mark S. Hanson and Robert Edelman --  |g 43.  |t Oral B Subunit-Killed Whole-Cell Cholera Vaccine /  |r Jan Holmgren and Charlotta Bergquist --  |g 44.  |t Attenuated Vibrio cholerae Strains as Live Oral Cholera Vaccines and Vectors /  |r James B. Kaper and Carol O. Tacket --  |g 45.  |t Novel Vaccines Against Tuberculosis /  |r Robert J. Wilkinson and Douglas B. Young --  |g 46.  |t New Approaches to Influenza Vaccine /  |r John J. Treanor, James C. King and Kenneth M. Zangwill --  |g 47.  |t Chimeric Vaccines Against Japanese Encephalitis, Dengue, and West Nile /  |r Konstantin V. Pugachev, Thomas P. Monath and Farshad Guirakhoo --  |g 48.  |t Challenges and Current Strategies in the Development of HIV/AIDS Vaccines /  |r Chad A. Womack, Margaret A. Liu and Barney S. Graham --  |g 49.  |t Vaccine Strategies to Prevent Dengue Fever /  |r Niranjan Kanesa-thasan, J. Robert Putnak and David W. Vaughn --  |g 50.  |t Vaccination Against the Hepatitis C Viruses /  |r Michael Houghton and Sergio Abrignani --  |g 51.  |t Live Vaccine Strategies to Prevent Rotavirus Disease /  |r Richard L. Ward, H. Fred Clark, Paul A. Offit and Roger I. Glass --  |g 52.  |t Vaccines Against Respiratory Syncytial Virus and Parainfluenza Virus Types 1-3 /  |r James E. Crowe, Jr., Peter L. Collins and Brian R. Murphy --  |g 53.  |t Developing a Vaccine Against Epstein-Barr Virus /  |r Denis Moss and Mandvi Bharadwaj --  |g 54.  |t Cytomegalovirus Vaccines /  |r David I. Bernstein and Stanley A. Plotkin --  |g 55.  |t Herpes Simplex Vaccines /  |r Richard J. Whitley --  |g 56.  |t Vaccines for Hantaviruses, Lassa Virus, and Filoviruses /  |r Connie Schmaljohn, Joseph B. McCormick, Gary J. Nabel and Alan Schmaljohn --  |g 57.  |t Development of a Vaccine to Prevent Infection with Group A Streptococci and Rheumatic Fever /  |r Michael F. Good, P. J. Cleary, James Dale, Vincent Fischetti, K. Fuchs, H. Sabharwal and J. Zabriskie --  |g 58.  |t Vaccines Against Group B Streptococcus /  |r Morven S. Edwards, Lawrence C. Paoletti and Carol J. Baker --  |g 59.  |t Overview of Live Vaccine Strategies Against Shigella /  |r Karen L. Kotloff, Thomas L. Hale, Eileen M. Barry and Philippe Sansonetti --  |g 60.  |t Oral Inactivated Whole Cell B Subunit Combination Vaccine Against Enterotoxigenic Escherichia coli /  |r Ann-Mari L. Svennerholm and Stephen J. Savarino --  |g 61.  |t Multivalent Shigella/Enterotoxigenic Escherichia coli Vaccine /  |r Eileen M. Barry and Myron M. Levine --  |g 62.  |t Vaccines Against Gonococcal Infection /  |r Timothy A. Mietzner, Christopher E. Thomas, Marcia M. Hobbs and Myron S. Cohen --  |g 63.  |t Vaccines Against Campylobacter jejuni /  |r David R. Tribble, Shahida Baqar and Daniel A. Scott --  |g 64.  |t Vaccines Against Uropathogenic Escherichia coli /  |r Solomon Langermann and W. Ripley Ballou, Jr. -- 
505 8 0 |g 65.  |t Vaccine Strategies Against Helicobacter pylori /  |r Karen L. Kotloff, Cynthia K. Lee and Giuseppe Del Giudice --  |g 66.  |t Vaccines for Staphylococcus aureus Infections /  |r Ali I. Fattom, Gary Horwith and Robert Naso --  |g 67.  |t Moraxella catarrhalis and Nontypable Haemophilus influenzae Vaccines to Prevent Otitis Media /  |r Philippe A. Denoel, Fabrice Godfroid, Joelle Thonnard, Cecile Neyt, David W. Dyer and Jan T. Poolman --  |g 68.  |t Vaccines for Chlamydia trachomatis and Chlamydia pneumoniae /  |r Andrew D. Murdin and Robert C. Brunham --  |g 69.  |t Overview of Vaccine Strategies for Malaria /  |r Michael F. Good and David Kemp --  |g 70.  |t Adjuvanted RTS,S and Other Protein-Based Pre-Erythrocytic Stage Malaria Vaccines /  |r D. Gray Heppner, Jr., James F. Cummings, Joe D. Cohen, W. Ripley Ballou, Jr., Christian F. Ockenhouse and Kent E. Kester --  |g 71.  |t Malaria: A Complex Disease that May Require A Complex Vaccine /  |r Stephen L. Hoffman, Denise L. Doolan and Thomas L. Richie --  |g 72.  |t Plasmodium falciparum Asexual Blood Stage Vaccine Candidates: Current Status /  |r Danielle I. Stanisic, Laura B. Martin, Robin F. Anders and Michael F. Good --  |g 73.  |t Malaria Transmission-Blocking Vaccines /  |r Allan Saul --  |g 74.  |t Vaccines Against Leishmania /  |r Farrokh Modabber, Steven G. Reed and Antonio Campos-Neto --  |g 75.  |t Vaccines Against Schistosomiasis /  |r Andre Capron, Gilles J. Riveau, Paul B. Bartley and Donald P. McManus --  |g 76.  |t Vaccines Against Entamoeba histolytica /  |r Christopher D. Huston and William A. Petri, Jr. --  |g 77.  |t Vaccines Against Human Hookworm Disease /  |r Peter J. Hotez, Zhan Bin, Alex Loukas, Jeff M. Bethony, James Ashcom, Kashinath Ghosh, John M. Hawdon, Walter Brandt and Philip K. Russell --  |g 78.  |t Principles of Therapeutic Vaccination for Viral and Nonviral Maligancies /  |r Drew M. Pardoll --  |g 79.  |t Vaccines Against Human Papillomavirus Infection /  |r John Boslego, Xiaosong Liu and Ian H. Frazer --  |g 80.  |t Active Immunization with Dendritic Cells Bearing Melanoma Antigens /  |r Ralph M. Steinman, Karolina Palucka, Jacques Banchereau, Beatrice Schuler-Thurner and Gerold Schuler --  |g 81.  |t Vaccine Against Alzheimer's Disease /  |r Roy M. Robins-Browne, Richard A. Strugnell and Colin L. Masters --  |g 82.  |t Vaccines Against Atherosclerosis /  |r Carl R. Alving --  |g 83.  |t Vaccine Therapy /  |r Donald S. Burke --  |g 84.  |t Vaccination-Based Therapies in Multiple Sclerosis /  |r Jacqueline Shukaliak-Quandt and Roland Martin --  |g 85.  |t Vaccine Therapy for Autoimmune Diabetes /  |r Irun R. Cohen --  |g 86.  |t Vaccines for the Treatment of Autoimmune Diseases /  |r David C. Wraith --  |g 87.  |t Vaccines to Treat Drug Addiction /  |r Paul R. Pentel and Dan E. Keyler --  |g 88.  |t Vaccines Against Agents of Bioterrorism /  |r Theodore J. Cieslak, Mark G. Kortepeter and Edward M. Eitzen, Jr. --  |g 89.  |t A Primer on Large-Scale Manufacture of Modern Vaccines /  |r Julie B. Milstien, Jean Stephenne and Lance Gordon --  |g 90.  |t Heterogeneity of Pediatric Immunization Schedules in Industrialized Countries /  |r James D. Campbell and Margaret Burgess. 
650 0 |a Vaccines.  |0 http://id.loc.gov/authorities/subjects/sh85141718 
650 7 |a Vaccines.  |2 fast  |0 http://id.worldcat.org/fast/fst01163573 
700 1 |a Levine, Myron M.  |q (Myron Max),  |d 1944-  |0 http://id.loc.gov/authorities/names/n90657798  |1 http://viaf.org/viaf/37071439 
901 |a ToCBNA 
903 |a HeVa 
035 |a (OCoLC)53913130 
929 |a cat 
999 f f |i ad846418-ddc7-55e2-8187-096f2664dbb6  |s f6cd332d-3345-50a2-b14c-768e82b065cc 
928 |t Library of Congress classification  |a QR189 .N489 2004  |l JCL  |c JCL-Sci  |i 6481095 
927 |t Library of Congress classification  |a QR189 .N489 2004  |l JCL  |c JCL-Sci  |e WIGO  |e CRERAR  |b 65519360  |i 7661406 
The William Roe and Ida Long Goodman Endowment Fund bookplate
The John Crerar Library bookplate

Similar Items